On March 2nd, the Genesense domestic gene sequencing platform's new product launch conference was successfully held in Pudong, Shanghai.
On March 2nd, Genesense successfully held a new product launch event for its domestic gene sequencing platform in Pudong, Shanghai. They unveiled their domestic gene sequencer, StarSeq®100, based on high-precision, high-performance, and high-sensitivity microscopic imaging technology. The new platform will provide an integrated, user-friendly, and reliable NGS solution for both scientific research and in vitro diagnosis, further helping to optimize the quality of scientific research services and improve clinical disease diagnosis.
During the opening ceremony, Dr. Mei Yan, founder and CEO of Genesense, gave an opening speech for the new product launch event. Around the company vision of "Genesense, accessible to everyone, everywhere," Dr. Mei Yan introduced Genesense , product strategy, and patent barriers. She emphasized Genesense positioning of "accelerating the transformation of applications from scientific research to clinical diagnosis" and is committed to creating low-cost, high-precision, easy-to-read, and fast detection multi-scenario applicable products. Dr. Mei Yan stated that the Human Genome Project has been ongoing for 25 years, and we are now experiencing a critical period of transformation from scientific research to clinical applications. Genesense's mission is to design expensive and complex scientific equipment into simple and durable medical instruments, change the current centralized sequencing method, and make sequencing technology more affordable and accessible to the public.
Dr. Mei Yan's speech
President of Shanghai Institute for Biomedical and Phamaceutical Technologies Daxu Fu, Vice President of the National Association of Health Industry and Enterprise Management Haibo Song, Executive President and Secretary-General of the Shanghai Biopharmaceutics Industry Association Shaoxiong Chen, Vice President of School of Microelectronics at Southern University of Science and Technology Professor Hao Yu, and Founding Dean of the Faculty of School of Engineering at the Hong Kong University of Science and Technology Professor Ping Keung KO were invited to attend the product launch event and gave wonderful speeches.
During the new product launch segment, Dr. Gengxin Chen, the CTO of Genesense, gave a detailed introduction of the new product. According to Dr. Chen, StarSeq®100 is a domestically produced small desktop NGS sequencer that is equipped with a high-sensitivity optical microscopic scanning imaging system. It features flexible dual flow-cells and four lanes for integrated library loading, sequencing, and data generation. StarSeq®100 has leading technical advantages: it miniaturizes and smartens the sequencing system through advanced semiconductor technology. The independently developed sequencing chemical reagent and high-density sequencing flow-cell make it compatible with mainstream NGS libraries accurately, quickly, and at low cost, and provide fast and high-quality services for local mass production and GMP process management. StarSeq®100 has Chinese IP and PCT property rights, supports multiple adaptive scenarios, including reproductive, pathogenic microorganisms, tumors, genetic diseases, and transcriptome sequencing. Its high GC extreme complexity library data quality and other sequencing outputs are comparable to American brands, while its Dup and Clean reads are superior to American platforms.
New product introduction by Dr.Chen
The launch and unveiling ceremony of the new product was also held at the press conference. Dr. Mei Yan, CEO of Genesense, and strategic partners Shanghai Institute for Biomedical and Phamaceutical Technologies and GoogolTech respectively signed Strategic Cooperation Agreement and took a group photo. Through this strategic cooperation, each party will fully utilize their respective strengths, closely cooperate, and jointly promote the transformation and implementation of NGS technology in scientific research services and clinical applications. We are committed to creating a fast, accurate, flexible, and cost-effective NGS platform to better serve scientific research and clinical workers and benefit the general public.
The launch and unveiling ceremony of StarSeq®100
The Strategic Cooperation Agreement signing ceremony (between Genesense and Shanghai Institute for Biomedical and Phamaceutical Technologies)
The Strategic Cooperation Agreement signing ceremony (between Genesense and Googol Technology)